The Oregon Clinical & Translational Research Institute has awarded three investigators grants through its Biomedical Innovation Program. The Biomedical Innovation Program aims to cultivate, select and provide strong program management for promising translational projects that develop new biomedical devices, diagnostics, and software. The primary objective of the program is to help bring innovative technologies from academia to the marketplace and thus to make a meaningful impact on human health.
The Biomedical Innovation Program is a collaboration between OCTRI and OHSU Technology Transfer and Business Development (TTBD), with additional funding and support from industry partners, Welch-Allyn and GE Healthcare.
Congratulations to our 2017 Biomedical Innovation Program Pilot Award Winners:
Dry Eye Treatment Device (abstract pending)
“The Biomedical Innovation Program meets a critical need at OHSU by funding promising early stage and potentially marketable technologies,” said OCTRI Director David Ellison, MD. “This funding, along with project management and mentorship, helps move the needle substantially, to put these technologies in the best possible position for commercialization where they can ultimately improve patient outcomes. We are very excited to fund these new technologies for 2017, and look forward to working closely with the investigators.”
Detailed information on all three awards, including project abstracts, is on the OCTRI website.